Skip to main content

Advertisement

Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

Fig. 1

AZD9291 inhibits GBM cell viability and proliferation. a GBM cells were treated by different concentrations of AZD9291 for 72 h. The cell viability was examined by CCK8 assay. Comparation of different sensitive of GBM cells to EGFR inhibitors (AZD9291, Erlotinib and Gefitinib). U251 (b) and U87 (c) cells were incubated with indicated concentrations of AZD9291, Erlotinib and Gefitinib for 72 h, respectively. Cell viability was assessed by CCK8 assay. d Mutation of EGFR abolishes the inhibitory activity of AZD9291 in GBM cells. EGFR WT and EGFR C797S mutant cells were treated with AZD9291 for 72 h, and then cell viabilities were examined by CCK8 assays. e and g Measurement of antiproliferation effects of AZD9291 by EdU incorporation assay. f and h Quantitative results of EdU incorporation assay. The numbers of proliferative cells were normalized to that of the control group. All the data were presented as means ± SEM from three independent experiments (*P < 0.05)

Back to article page